Modality
Peptide
MOA
GLP-1/GIP
Target
KRASG12D
Pathway
RAS/MAPK
GIST
Development Pipeline
Preclinical
~Aug 2021
→ ~Nov 2022
Phase 1
~Feb 2023
→ ~May 2024
Phase 2
Aug 2024
→ Dec 2031
Phase 2Current
NCT07149149
905 pts·GIST
2024-08→2031-12·Terminated
905 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-12-095.7y awayPh3 Readout· GIST
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2/3
Termina…
Catalysts
Ph3 Readout
2031-12-09 · 5.7y away
GIST
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07149149 | Phase 2/3 | GIST | Terminated | 905 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 |